(Q37820701)

23 August 2017

1 reference

title

Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems (English)

1 reference

23 August 2017

0 references

A Scheifes

1

1 reference

23 August 2017

J J Stolker

2

1 reference

23 August 2017

A C G Egberts

3

1 reference

23 August 2017

H L I Nijman

4

1 reference

23 August 2017

E R Heerdink

5

1 reference

23 August 2017

publication date

13 December 2010

1 reference

Journal of Intellectual Disability Research

23 August 2017

published in

1 reference

23 August 2017

volume

55

1 reference

23 August 2017

issue

7

1 reference

23 August 2017

page(s)

650-664

1 reference

Reducing antipsychotic medication in people with a learning disability.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Clinical effects of methylphenidate and thioridazine in intellectually subaverage children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Diagnosis and treatment of aggression in individuals with developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

The effect of quetiapine on aggression and hostility in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Mental ill-health in adults with intellectual disabilities: prevalence and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Prevalence and types of aggressive behaviour among adults with intellectual disabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Effect of Risperidone on Hostility in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

How to assess the external validity of therapeutic trials: a conceptual approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of SCH-12679 and thioridazine in aggressive mental retardates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A double-blind pilot study of risperidone in the treatment of conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Need for medicine-based evidence in pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Representation of the elderly, women, and minorities in heart failure clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Differential response of operant self-injury to pharmacologic versus behavioral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Psychopharmacology and mental retardation: a 10 year review (1990-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone in children with autism: randomized, placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour: a double-blind study with zuclopenthixol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Aggressive behaviour in adults with intellectual disability: defining the role of drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Eligibility of Alzheimer's disease clinic patients for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Reporting the study populations of clinical trials. Clear transmission or static on the line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Prevalence and cluster typology of maladaptive behaviors in a geographically defined population of adults with learning disabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Efficacy of phenelzine and haloperidol in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Psychotropic drug use in intellectually disabled group-home residents with behavioural problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Physical aggression towards others in adults with learning disabilities: prevalence and associated factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

The effect of milenperone on the aggressive behavior of psychogeriatric patients. A double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2788.2010.01353.X

10.1111/J.1365-2788.2010.01353.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference